Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT06417814
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 235
- Registration Number
- NCT06412471
- Locations
- 🇨🇳
Institute of The Hunan Cancer Hospital, Changsha, China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 117
- Registration Number
- NCT06413992
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Tel Aviv Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT06407310
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
- Conditions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 68
- Registration Number
- NCT06403878
- Locations
- 🇨🇳
West-China Hospital, Chengdu, China
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 73
- Registration Number
- NCT06404736
- Locations
- 🇨🇳
Zhimin Shao, Shanghai, Not US/Canada, China
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- Conditions
- Interventions
- Procedure: NephrectomyProcedure: Computed TomographyProcedure: Bone ScanDrug: CarboplatinBiological: DactinomycinOther: Patient ObservationProcedure: Magnetic Resonance ImagingDrug: DoxorubicinDrug: CyclophosphamideProcedure: Ultrasound ImagingDrug: VincristineDrug: EtoposideProcedure: X-Ray ImagingDrug: IrinotecanProcedure: Positron Emission Tomography
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1656
- Registration Number
- NCT06401330
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 44
- Registration Number
- NCT06391008
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 240
- Registration Number
- NCT06368817
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.